Indaptus Therapeutics Inc (INDP) Stock Price, Quote & News

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 427 2727

Website: indaptusrx.com

Address:

Three Columbus Circle, 15th Floor, New York, United States

FreeCashFlowFlow Aug. 27 at 9:48 AM

$INDP trading near support, reaction here could define next trend.

1 · Reply

topstockalerts Aug. 20 at 10:57 PM

After Hours Top Gainers PT2 $SCNI $INDP $ZENV $QTTB $AACG

0 · Reply

stockanalysis_ Aug. 20 at 8:49 PM

After Hours Gainers: $VS $THAR $GDEV $EFOI $INDP Bookmark this screener here: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading

0 · Reply

foobars Aug. 15 at 3:01 PM

$INDP invested a few years ago....

0 · Reply

RedDogSailor Aug. 14 at 3:10 PM

$INDP That’s a big offering. And the SP barely moved. 🤷‍♂️

1 · Reply

DonCorleone77 Aug. 13 at 8:51 PM

$INDP Indaptus Therapeutics files $200M mixed securities shelf

0 · Reply

TwongStocks Aug. 13 at 12:18 PM

$INDP Earnings release and 10-Q filed. https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000164117225023333/form10-q.htm • $6.2m in cash as of Jun 30. Enough to fund operations into Q4 2025. • Net loss of $5.23m, $9.09 per share • As of Aug 12 there were 1,106,529 shares outstanding (after conversion of the convertible notes in July). • "In June 2025 we announced the dosing of the first participant in the Combination Study and by August 2025 we had enrolled 6 participants, and we have seen one related serious adverse event of CRS in 1 participant that has resolved within 72 hours."

1 · Reply

Biomechanika Aug. 13 at 12:14 PM

$INDP "In June 2025 we announced the dosing of the first participant in the Combination Study and by August 2025 we had enrolled 6 participants, and we have seen one related serious adverse event of CRS in 1 participant that has resolved within 72 hours. "

0 · Reply

Beginner999 Aug. 12 at 12:58 PM

$INDP keeps giving

0 · Reply

AutoAZTrader Aug. 11 at 7:19 PM

$INDP Shit, I thought we were going to have an up day; delusional again. What the fuck are these assholes doing?

0 · Reply

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025, 8:14 AM EDT - 2 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jun 25, 2025, 7:00 AM EDT - 2 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Jun 13, 2025, 8:00 AM EDT - 2 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

May 14, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 20, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 18, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 13, 2025, 7:30 AM EDT - 5 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:15 PM EDT - 5 months ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 4, 2025, 8:00 AM EST - 6 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Feb 25, 2025, 8:00 AM EST - 6 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 5, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Jan 8, 2025, 8:00 AM EST - 8 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Nov 22, 2024, 8:36 AM EST - 9 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 11, 2024, 8:00 AM EST - 10 months ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 7, 2024, 8:00 AM EST - 10 months ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Oct 23, 2024, 8:00 AM EDT - 11 months ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Jan 4, 2024, 8:00 AM EST - 1 year ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Nov 6, 2023, 4:01 PM EST - 1 year ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 9:01 AM EDT - 1 year ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 14, 2023, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Feb 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Dec 13, 2022, 7:30 AM EST - 2 years ago

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Nov 10, 2022, 4:05 PM EST - 3 years ago

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics to Present at the LD Micro Main Event XV

FreeCashFlowFlow Aug. 27 at 9:48 AM

$INDP trading near support, reaction here could define next trend.

1 · Reply

topstockalerts Aug. 20 at 10:57 PM

After Hours Top Gainers PT2 $SCNI $INDP $ZENV $QTTB $AACG

0 · Reply

stockanalysis_ Aug. 20 at 8:49 PM

After Hours Gainers: $VS $THAR $GDEV $EFOI $INDP Bookmark this screener here: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading

0 · Reply

foobars Aug. 15 at 3:01 PM

$INDP invested a few years ago....

0 · Reply

RedDogSailor Aug. 14 at 3:10 PM

$INDP That’s a big offering. And the SP barely moved. 🤷‍♂️

1 · Reply

DonCorleone77 Aug. 13 at 8:51 PM

$INDP Indaptus Therapeutics files $200M mixed securities shelf

0 · Reply

TwongStocks Aug. 13 at 12:18 PM

1 · Reply

Biomechanika Aug. 13 at 12:14 PM

0 · Reply

Beginner999 Aug. 12 at 12:58 PM

$INDP keeps giving

0 · Reply

AutoAZTrader Aug. 11 at 7:19 PM

$INDP Shit, I thought we were going to have an up day; delusional again. What the fuck are these assholes doing?

0 · Reply

Biomechanika Aug. 11 at 11:12 AM

$INDP Near all time low again. Not surprising since - as it was said numerous times - no value to date and cash at hand is really low. It will be like this till they prove Decoy is working well with combination. They mentioned in a tweet that initial data will be presented soon. ER also anticipated this week.

0 · Reply

Beginner999 Aug. 9 at 11:58 PM

$INDP light work

1 · Reply

AverageAndy Aug. 8 at 2:46 PM

$INDP I don’t think there is a worst stock to own. This is crazy. “I’ve lost so much money in this company.”

1 · Reply

AutoAZTrader Aug. 6 at 4:07 PM

$INDP Markets screaming up and this down 5%. This is going back under $1. Fuck.

1 · Reply

Indpwhenhigh Aug. 5 at 5:57 PM

$INDP Your mother did not give birth to you

0 · Reply

Ev3rM0r3 Aug. 5 at 2:18 PM

$INDP well thats my exit, after the split and now down another 5 in out about 8k$. I'll take the wash and call it a half decade. I encourage everyone else to leave as well, stock is dead, and the last few times i've seen this bankruptcy comes next.

0 · Reply

wjmax Aug. 5 at 2:15 PM

$NWBO Do $INDP investors know that their drug is the perfect immune booster that can be combined with the Direct? $SNDX CSF1R inhibitor can overcome immunosuppression from tumor-associated macrophages. That's why Incyte had the collaboration.

2 · Reply

wjmax Aug. 5 at 1:31 PM

$NWBO What happened to $SNDX and $INDP? Is it related to $NWBO?

2 · Reply